Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Uterine Leiomyosarcoma: early-phase trial registry
2 of 4 indexed Uterine Leiomyosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Uterine Leiomyosarcoma: 4 US clinical trials tracked, 2 recruiting.
Uterine Leiomyosarcoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is GOG Foundation, running 1 of these trials.
Enrollment posture brief
Registry condition uterine-leiomyosarcoma
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Uterine Leiomyosarcoma lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Uterine Leiomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Uterine Leiomyosarcoma is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
M.D. Anderson Cancer Center
NCT07076186
Letrozole in Uterine Leiomyosarcoma
GOG Foundation
NCT05649956
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
Stanford University
NCT04727242
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
National Cancer Institute (NCI)
NCT00378911
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Uterine Leiomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Uterine Leiomyosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Uterine Leiomyosarcoma page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Uterine Leiomyosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GOG Foundation sponsors the most Uterine Leiomyosarcoma trials on record, review their full trial history before evaluating a specific study. See GOG Foundation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uterine Leiomyosarcoma condition card totals 4 registered trials; most-linked intervention sunitinib malate; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.